NERV - Minerva Neurosciences, Inc.
7.3
-0.640 -8.767%
Share volume: 213,046
Last Updated: 03-11-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.16%
PREVIOUS CLOSE
CHG
CHG%
$7.94
-0.64
-0.08%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-01-2024 | 08-06-2024 | 11-05-2024 | 02-25-2025 | 05-13-2025 | 08-14-2025 | 11-05-2025 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 6.682 M | 6.278 M | 4.367 M | 4.522 M | 3.903 M | 3.374 M | 2.844 M | |
| Selling general and admin | 2.515 M | 2.417 M | 2.479 M | 2.539 M | 2.540 M | 2.076 M | 1.919 M | |
| Research and development | 4.167 M | 3.860 M | 1.888 M | 1.983 M | 1.362 M | 1.298 M | 925.377 K | |
| Total expenses | 6.682 M | 6.278 M | 4.367 M | 4.522 M | 3.903 M | 3.374 M | 2.844 M | |
| -6.05% | -30.44% | 3.56% | -13.69% | -13.55% | -15.70% | |||
| Operating income | -6.682 M | -6.278 M | -4.367 M | -4.522 M | -3.903 M | -3.374 M | -2.844 M | |
| Ebit | -6.682 M | -6.278 M | 22.212 M | -4.522 M | -3.903 M | -3.374 M | -2.844 M | |
| Pretax income | -8.574 M | -8.229 M | 22.526 M | -5.723 M | -3.745 M | -3.237 M | -2.738 M | |
| -4.03% | -373.75% | -125.41% | -34.57% | -13.54% | -15.44% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -8.569 M | -8.233 M | 22.513 M | -4.272 M | -3.753 M | -3.259 M | -2.744 M | |
| 3.91% | 373.43% | -118.98% | 12.15% | 13.17% | 15.79% |